Send the following on WhatsApp
Continue to Chathttps://forschung.kssg.ch/en/projects/1022-a-phase-3-randomized-study-comparing-bortezomib-lenalidomide-and-dexamethasone-vrd-followed-by-ciltacabtagene-autoleucel-a-chimeric-antigen-receptor-t-cell-car-t-therapy-directed-against-bcma-versus-bortezomib-lenalidomide-and-dexamethasone-vrd-followed-by-lenalidomide-and-dexamethasone-rd-therapy-in-participants-with-newly-diagnosed-multiple-myeloma-for-whom-hematopoietic-stem-cell-transplant-is-not-planned-as-initial-therapy